Research and Markets (http://www.researchandmarkets.com/research/cnk25v/hivaids) has announced the addition of the "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth" report to their offering.
Stribild Introduction to Reinforce HIV/AIDS Revenues as Key Patents Expire
Gilead Science's combination drug Stribild (previously known as the Quad pill) is expected to bolster the HIV/AIDS therapeutics market as a number of significant medications go off-patent over the next few years, states business intelligence provider GBI Research in its latest publication.
Forecasts from the firm's latest report indicate that the global HIV/AIDS therapeutics market will increase in value at a Compound Annual Growth Rate (CAGR) of 7% between the years 2011 and 2018, from $13.5 billion to $21.8 billion.
As a consequence of the on-going patent-cliff, this predicted growth rate is less than the market experienced in previous years. Between 2004 and 2011, the market experienced a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva and Reyataz (both produced by Bristol-Myers Squibb) in 2014 and 2017 respectively, a more modest increase is predicted.
However, the market is not without promise. The multi-class fixed dose combination tablet from Gilead Sciences, Atripla, saw global revenue increase from $2.9 billion in 2010 to $3.2 billion last year, while potential blockbuster Stribild was approved by the US Food and Drug Administration in August of this year and is expected to make a major impact.
Gilead announced Stribild's initial price as $28,500, which is one-third greater than that of Atripla, but with impressive efficacy and strong patient compliance, GBI Research do not expect this higher cost to be a significant barrier to widespread use.
Last year's sales figures show Gilead as being the greatest revenue shareholder of the world's top seven markets, with 36%. With less than half of that number, Bristol-Myers Squibb came second with 16%, while ViiV Healthcare completed the top three with a 13% segment.
This report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
- Gilead Sciences, Inc
- GlaxoSmithKline (GSK)
- Abbott Laboratories
- Johnson & Johnson (J&J)
For more information visit http://www.researchandmarkets.com/research/cnk25v/hivaids.